MeiraGTx Holdings (MGTX) Change in Accured Expenses (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Change in Accured Expenses of $22.0 million for Q4 2025, down 5.96% on a YoY basis from $23.4 million in Q4 2024, and down 45.24% quarter-over-quarter from $40.2 million in Q3 2025.
MeiraGTx Holdings (MGTX) Change in Accured Expenses (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Change in Accured Expenses for 9 years, with the latest figure at $22.0 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses fell 5.96% year-over-year to $22.0 million; the trailing twelve-month figure through Dec 2025 stood at $49.5 million (up 154728.12% YoY), and the FY2025 full-year result was $49.5 million, up 154728.12% from the prior year.
- Change in Accured Expenses for Q4 2025 stood at $22.0 million, down from $40.2 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $40.2 million in Q3 2025, with the low at -$25.0 million in Q2 2024.
- Historically, Change in Accured Expenses has averaged $3.0 million across 5 years, with a median of $2.0 million in 2022.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 15862.5% — and 2025, when it soared 2444.49%.
- MeiraGTx Holdings' Change in Accured Expenses stood at $8.1 million in 2021, then tumbled by 70.36% to $2.4 million in 2022, then jumped by 420.6% to $12.6 million in 2023, then soared by 86.13% to $23.4 million in 2024, then decreased by 5.96% to $22.0 million in 2025.
- The last three Change in Accured Expenses figures came in at $22.0 million (Q4 2025), $40.2 million (Q3 2025), and -$9.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 931,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 70.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 21.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.99 Mn |
| Dec 31, 2025 | 21.99 Mn |
| Sep 30, 2025 | 40.15 Mn |
| Sep 30, 2025 | 40.15 Mn |
| Jun 30, 2025 | -9.01 Mn |
| Jun 30, 2025 | -9.01 Mn |
| Mar 31, 2025 | -3.59 Mn |
| Mar 31, 2025 | -3.59 Mn |
| Dec 31, 2024 | 23.38 Mn |
| Dec 31, 2024 | 23.38 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | -24.97 Mn |
| Jun 30, 2024 | -24.97 Mn |
| Mar 31, 2024 | 37,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 12.56 Mn |
| Dec 31, 2023 | 12.56 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Sep 30, 2023 | 3.32 Mn |